ClinicalTrials.Veeva

Menu

Identification and Analysis of Immunomodulatory Molecules in Patients With Hematologic Disorders and Healthy Volunteers

The University of Texas System (UT) logo

The University of Texas System (UT)

Status

Completed

Conditions

Healthy Volunteers
Hematologic Diseases

Treatments

Genetic: Isolation of genomic DNA

Study type

Observational

Funder types

Other
Other U.S. Federal agency

Identifiers

NCT00223483
HSC20040268H

Details and patient eligibility

About

This research study goal is to analyze the plasma and the cells that make up part of the immune system. We want to learn how the plasma and cells work. These may influence why one person will develop an infection and another will not, or why one person develops severe symptoms of a disease while others remain without symptoms.

Full description

This research study goal is to analyze the plasma and the cells that make up part of the immune system. These cells, called white cells or leukocytes, are present in blood. We want to learn how these cells work to prevent infection and how they respond after an infection occurs. We also want to study certain molecules present on the plasma, on or in these cells, and the genetic material that allows these molecules to be made. These molecules may influence why one person will develop an infection and another will not, or why one person develops severe symptoms of a disease while others remain without symptoms. This study may increase our understanding of a variety of diseases including infections such as HIV, allergic diseases such as asthma, joint diseases such as rheumatoid arthritis, certain cancers, and the rejection process that sometimes occurs after transplantation of an organ.

Enrollment

512 patients

Sex

All

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Must be able to give blood
  • Must be able to give informed consent
  • Signed, written informed consent

Exclusion criteria

  • Individuals with a history severe anemia, inadequate venous access, severe blood or coagulation disorders.
  • Pregnant women are excluded because it is a unique immunotolerant state and will alter the profile of immunomodulatory molecules.

Trial contacts and locations

2

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems